20% Upper Circuit: Pharma Stock Skyrockets After Announcing Strong Q4 Earnings

Synopsis: The share of this pharma company hit a 20 percent upper circuit after strong Q4 FY26 earnings driven by anesthetic demand, robust margins, and export-led growth momentum.

The share of this company, which  is an Indian, Mumbai-based manufacturer of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, gained investor traction after reporting strong Q4 numbers

With a market capitalization of Rs 7,796 crore, Supriya Lifescience Ltd’s shares made a day high of Rs 968.70 per share, hitting the upper circuit of 20 percent from its previous day’s close price of Rs 807.25 per share. The share of this company gave a return of  29 percent over the last year.

Result overview

• QoQ View: The revenue from operations grew by 34.0 percent to Rs 276.53 crore in Q4 FY26 from Rs 206.44 crore in Q3 FY26, and EBITDA grew by 35.4 percent to Rs 97.62 crore in Q4 FY26 from Rs 72.08 crore in Q3 FY26. This was accompanied by a net profit growth of 49.4 percent to Rs 74.23 crore in Q4 FY26 from Rs 49.68 crore in Q3 FY26, resulting in an EPS growth of 49.4 percent to Rs 9.22 per share from Rs 6.17 per share in Q3 FY26.
• YoY View: The revenue from operations grew by 50.2 percent to Rs 276.53 crore in Q4 FY26 from Rs 184.11 crore in Q4 FY25, and EBITDA grew by 44.4 percent to Rs 97.62 crore in Q4 FY26 from Rs 67.58 crore in Q4 FY25. This was accompanied by a net profit growth of 47.4 percent to Rs 74.23 crore in Q4 FY26 from Rs 50.37 crore in Q4 FY25, resulting in an EPS growth of 46.6 percent to Rs 9.22 per share in Q4 FY26 from Rs 6.29 per share in Q4 FY25.
• Fiscal Year Comparison: The annual revenue from operations grew by 18.9 percent to Rs 827.87 crore in FY26 from Rs 696.48 crore in FY25, and Annual EBITDA rose 12.8 percent to Rs 294.05 crore in FY26 compared to Rs 260.79 crore in FY25, while the full-year EBITDA margin compressed slightly to 35.5 percent from 37.4 percent.

Annual net profit grew by 11.3 percent to Rs 209.12 crore in FY26 up from Rs 187.96 crore in FY25, bringing the full-year EPS to Rs 25.98 per share compared to Rs 23.35 per share in the prior year.

Q4 Business Performance

• Margins Remain Healthy Despite Slight Compression: EBITDA margin stayed strong at 35.3 percent, though it moderated slightly from 36.7 percent in Q4 FY25. The minor contraction reflects higher operating costs linked to capacity expansion and product scale-up, while the company still maintained industry-leading profitability levels.
• Growth Led by Core Anesthetic Portfolio: The anesthetic segment continued to act as the primary growth driver, contributing 54 percent of total revenues in FY26 versus 49 percent in FY25. Alongside this, increasing traction of vitamins improved to 12 percent, Europe stayed the largest market at 40 percent, followed by Asia at 33 percent and LATAM at 20 percent.
• Strong Export Base and Geographic Stability: Exports remained a key strength, contributing around 82 percent of FY26 revenues. Europe continued to be the largest market, followed by Asia and LATAM, indicating stable demand across regulated international markets and reinforcing the company’s global positioning.
• Capacity Expansion and Long-Term Growth Investments: Operational performance was supported by higher capacity utilisation of 74 percent in FY26, compared to 70 percent in FY25. The ramp-up of the Lote facility, commissioning of new formulation lines at Ambernath, and ongoing infrastructure expansion initiatives strengthen long-term production capability and growth visibility.
• Management Commentary: Dr. Satish Wagh of Supriya Lifescience Limited said FY26 performance was driven by steady demand in key therapeutics, strong regulated market traction, and new product launches. He highlighted capacity expansion, R&D investments, and commercialization of the Liquid Anesthetic product as key growth drivers supporting long-term sustainable business momentum.

About the Company

Supriya Lifescience Limited is a global active pharmaceutical ingredient (API) manufacturer founded in 1987, headquartered in Mumbai with a key facility in Khed, Ratnagiri. The company operates globally compliant plants certified by USFDA, EDQM, WHO, PMDA, KFDA, ANVISA and others, supported by strong R&D, multiple CEPs and USDMFs. 

It primarily develops intermediates and APIs for innovator and generic companies and also operates as a CMO partner, guided by strict EHS standards and ethical practices

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 20% Upper Circuit: Pharma Stock Skyrockets After Announcing Strong Q4 Earnings appeared first on Trade Brains.